Background {#Sec1}
==========

Mature cystic teratoma of the ovary (MCTO) may occur in 10--20% of women during their lifetime \[[@CR1]\]. The biological behavior of MCTO is benign, while 0.17--2% of MCTO may undergo malignant transformation \[[@CR2]\]. There are various histological types of malignant transformation such as squamous cell carcinoma (SCC), adenocarcinoma, small cell carcinoma, sarcoma, malignant melanoma and mixed histology \[[@CR3]\]. Among them SCC transformation in MCTO is most common, accounting for 80% of all malignant transformation \[[@CR4]\].

The clinical manifestations of SCC transformation in MCTO are not specific. Tumor of early stage is often detected accidentally during physical examination or postoperative pathological examination \[[@CR5]\], while palpable mass, bloating and abdominal pain are often present in advanced stage \[[@CR6], [@CR7]\]. Acute abdomen may occur due to tumor torsion or rupture \[[@CR8]\]. Moreover, preoperative imaging investigation and laboratory tests are not specific, either.

Large-scale clinical prospective study is not feasible because of the low incidence of SCC transformation in MCTO and the published cases are scattered, and the optimal treatment for SCC transformation in MCTO remains unclear \[[@CR9]\]. Some doctors hold the idea that since SCC originates from epithelium so its treatment should follow principles that of epithelial ovarian cancer \[[@CR10], [@CR11]\], some believe that the treatment should refer to SCC of other sites \[[@CR12]\], and some suggest that since the malignancy presents on the basis of MCTO, which is a kind of ovarian germ cell tumors, the treatment can refer to that of ovarian germ cell malignancy. However, the surgical principle and postoperative adjuvant therapy of epithelial ovarian cancer, ovarian germ cell tumors and squamous cell carcinoma are different \[[@CR13]\]. So it is of great importance to find out the most effective treatment.

In this study, we systematic review published data about SCC transformation in MCTO from 1977 to 2016 and cases from Qilu Hospital, Shandong University, aiming to further elucidate the clinical characteristics, prognostic factors and treatment of SCC transformation in MCTO and provide evidence of clinical management of this rare malignancy.

Methods {#Sec2}
=======

We searched PubMed database with key words of "squamous cell carcinoma of mature cystic teratoma ovary", "malignant transformation mature teratoma ovary", "second tumor teratoma", "malignant dermoid cyst ovary", "MCTO squamous cell carcinoma", "SCC in MCTO", "mature cystic teratoma malignant". Cases of SCC transformation in MCTO published from January 1977 to October 2016 were included. Only cases with specific histology, invasive behavior and available individual patient data were included (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). The MCTO cases of Qilu hospital between January 2005 and October 2016 were reviewed and 6 cases SCC transformation in MCTO were included in this study. Clinicopathologic information, including age, tumor size, symptoms, stage, histological grade, surgical approach, adjuvant therapy, survival status and follow-up time were collected and analyzed. We used SPSS (version 21.0, for Windows) for statistical analysis. Data analysis was performed with descriptive statistics, chi-square test, Kaplan-Meier plots with Log-rank test, univariate and multivariate Cox proportional hazards regression model. A two-tailed *P* \< 0.05 value was defined as statistically significant.

Results {#Sec3}
=======

A total of 435 cases were included in this study, with 429 SCC transformation in MCTO cases from 45 case series and 54 case report \[[@CR3]--[@CR8], [@CR10]--[@CR12], [@CR14]--[@CR103]\] (Table [1](#Tab1){ref-type="table"}), and 6 cases from Qilu Hospital, Shandong University.Table 1Summary data from published literatures on SCC transformation in MCTOa. Case series on SCC transformation in MCTOCountry of studyAuthor (year)Number of casesAgeStageGradeIIIIIIIVNA123NAJapanYoshida et al. (2016)237--6422JapanTazo et al. (2016)245--5322KoreaPark et al. (2015)248--67112UKAraujo et al.(2015)435--4421122ChinaChiang et al.(2015)432--54224TurkeyKoc et al. (2015)1228--62812112USARojas et al. (2015)255--71112KoreaChoi et al.(2014)435--51222PakistanHannan et al. (2014)350--66213ThailandOranratanaphan et al. (2013)434--70224UKPowell et al. (2013)642--65426TurkeyUlker et al.(2012)343--4733ChinaChiang et al. (2011)332--541212JapanSakuma et al.(2010)1529--7783315235IndiaGupta et al. (2009)230--6522KoreaPark et al.(2008)1229--756152JapanIwasa et al.(2008)2132--84142416105UKHurwitz et al.(2007)1227--69822138JapanYamaguchi et al.(2007)1129--67712111IndiaBal et al. (2007)435--4544KoreaPark et al. (2007)531--753115USADos Santos et al. (2007)1737--7585417KoreaRim et al. (2006)719--71611123ChinaWen et al. (2006)232--52211ThailandTangjitgamol et al. (2003)442--742114JapanSumi et al. (2001)353--721113ChinaChen et al. (2001)330--65213JapanHirai et al. (2000)361--72213JapanEmoto et al. (2000)539--73155ChinaShen et al. (1998)1030--822132210JapanYoshioka et al. (1998)441--68314JapanKikkawa et al. (1998)3728--87195139765ChinaTseng et al. (1996)2621--7713210121212TurkeyZorlu et al. (1996)328--4233USAPins et al. (1996)1621--75763277JapanHirakawa et al. (1989)2832--84183511141031JapanKimura et al. (1989)637--80231231JapanKashimura et al. (1989)749--785117NetherlandsChadha et al. (1988)1635--7381528152UKRibeiro et al. (1987)625--6451123JapanTamaya et al. (1984)230--6122UKStamp et al. (1983)1836--761818AustraliaCurling et al. (1979)1046--73622622SpainAmerigo et al. (1978)542--592215USAKrumerman et al. (1976)451--652114b. Case reports on SCC transformation in MCTOCountry of studyAuthor (year)AgeStageStageUKGooneratne et al. (2015)63II3USABlack et al. (2015)74INAIndiaSrivastava et al. (2015)60II2GreeceKalampokas et al. (2014)56I1USAYarmohammadi et al. (2014)48III3IndiaPatni et al. (2014)53INAKoreaYun et al. (2013)30I1TurkeyBalik et al. (2013)66III2PakistanChaudhry et al. (2013)43I2IndiaMandal et al. (2012)56III1TurkeyAvci et al. (2012)52I2USASong et al. (2012)73II1SerbiaAmidzic et al. (2012)80I1USABaughn et al. (2011)58INATurkeyKahraman et al. (2011)63INAIndiaPrasad et al. (2011)40III1NigeniaBadmos et al. (2011)46IINAJapanIto et al. (2011)78IINAUSAParithivel et al. (2011)68II3USAAlatassi et al. (2011)49IINAIndiaMadan et al. (2010)37I1GreeceKorkontzelos et al. (2010)56INAJapanHosokawa et al. (2010)52INAGermanyBudiman et al. (2010)41I3KoreaLim et al. (2009)68IIINAIranShariat-Torbaghan et al. (2009)63IV3BrazilSilva et al. (2009)75I1ChinaWang et al. (2008)39III2ChinaDing et al. (2008)62IIINAJapanMekaru et al. (2008)33INAIndiaSantwani et al. (2008)40INATurkeyArioz et al. (2007)31II2UKSanghera et al. (2006)48IINAGreeceFilippakis et al. (2006)41INAUSASpannuth et al. (2005)52II3ChinaLai et al. (2005)47IIINAUKKaranjgaokar et al. (2005)66III2UKMechery et al. (2004)51I3JapanTakemori et al. (2003)69IINAUSAPowell et al. (2003)67IIINACanadaDo et al. (2002)44II2CanadaMayer et al. (2002)37II2USANoumoff et al. (2001)36I3JapanTakeuchi et al. (2000)72IINAFranceKurtz et al. (1999)34IIINAJapanIsoda et al. (1999)56IINAUSALee et al. (1999)50II1UKAs et al. (1997)33II2USAGriffiths et al. (1995)76III2USAKung et al. (1994)44I3USARose et al. (1993)42IIINAUSAChristopherson et al. (1989)26III1USASelim et al. (1984)43INAJapanMitui et al. (1983)72III1

Retrospective chart review {#Sec4}
--------------------------

From January 2005 to October 2016, there were 1836 MCTO cases in Qilu Hospital, Shandong University, 6 cases of them were SCC transformation in MCTO, accounting for 0.3% of all MCTO cases. Mean age of the 6 patients was 53.7 (range 26--68) years. Follow-up time was 3--72 months. 2 cases underwent comprehensive staging surgery of ovarian cancer. 1 patient received fertility-sparing surgery. For this patient, the diagnosis of SCC transformation in MCTO in stageIC was made after initial left ovarian tumor resection, and then she received fertility-sparing staging surgery. 3 widespread metastatic cases underwent cytoreductive surgery and 1 of them was optimally debulked (residual tumor volume less than 1 cm). 4 cases were treated with postoperative chemotherapy. All of them received TC regimen for 1--6 cycles. No case was treated with postoperative radiotherapy. Details on clinical characteristics were listed in Table [2](#Tab2){ref-type="table"}.Table 2Clinical features of SCC transformation in MCTO from a retrospective chart reviewCaseAge (years)SymptomsElevated tumor markerDiameter (cm)SurgeryOptimal debulkingRuptureGradeStageAdjuvant therapyFollow-up (status, months)1≥45Accidental finding--7TH + LSO + BPLND + omentectomyYN3IATC × 1LOST, 32≥45PainCA125(179.5 U/mL), CEA (6.1 ng/mL)12TH + BSO + omentectomy + BPLND + BPALND + peritoneal tumor resectionYN2IIBTC × 6NED, 723≥45Pain, distensionCA125(363.8 U/mL), CEA (25.2 ng/mL)15TH + BSO + appendectomyYN2IIIBTC × 1DOD, 94≥45Pain, distension, feverCA125(62.9 U/mL), SCC (7.3 ng/mL)20TH + BSO + omentectomy + partial peritoneal resectionNPreoperative2IIIC--LOST, 245≥45Pain, vaginal bleedingCA125(144.7 U/mL), SCC (15.1 ng/mL), CA199(119.1 U/mL), CEA (40.9 ng/mL)25TH + BSO + tumor resection + sigmoidectomyNIntraoperative3IIIC--DOD, 156\<45Accidental findingCA125 (42.8 U/mL), CA199(97.1 U/mL)5Initial surgery: Left ovarian cystectomy\
Restaging surgery: LSO + omentectomy + BPLND + BPALNDYN3ICTC × 3NED, 8*TH* total hysterectomy, *LSO* left salpingo-oophorectomy, *BSO* bilateral salpingo-oophorectomy, *BPLND* bilateral pelvic lymph node dissection, *BPALND* bilateral para-aortic lymph node dissection, *TC* taxol/carboplatin, *Y* yes, *N* no, *DOD* die of disease, *NED* no evidence of disease

Imaging investigation indicated cystic-solid mass with blood flow signal and enhancement. Grossly, the tumor consisted of cystic and solid components. There were typical components of MCTO such as hair, oil, sebaceous glands and epidermis. Microscopically, there were increased layers of squamous epithelium, disorderly arranged cells, squamous cells with atypia, irregular nuclei and necrosis (Fig. [1](#Fig1){ref-type="fig"}). All 6 cases were positive staining for p63, negative staining for p16, moderate to strong positive staining for Ki67 and alteration in p53. Detailed immunohistochemical panel is listed in Table [3](#Tab3){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Histological features of SCC transformation in MCTO from a retrospective chart reviewTable 3Immunohistochemical panel of SCC transformation in MCTO from a retrospective chart reviewAntibodySourceDilutionCase 1Case 2Case 3Case 4Case 5Case 6Ki67Abcam1:250+++++++++++++p16Abcam1:100------------p63Abcam1:500++++++++++CK8/18Dakoprediluted++++++, 5%+++++++++++CK5/6Dakoprediluted++++++++++++++++p53Abcam1:100+, focal+++--+++++++The antibody reaction was graded according to the intensity od staining: - (negative), + (weak), ++(moderate), +++ (strong)

Systematic review {#Sec5}
-----------------

Of the 435 cases of SCC transformation in MCTO, follow-up information was available for 363 cases and the follow-up time ranged from 0.4 months to 276 months. 146 (40.2%) cases ended up with death during the follow-up. Mean age of diagnosis was 53.5 (range 19--87) years. 121(27.9%) were\<45 year old while 313(72.1%) were ≥ 45 years old (Table [4](#Tab4){ref-type="table"}). Age ≥ 45 years was related with worse prognosis compared with patients\<45 (*P* \< 0.01) (Table [5](#Tab5){ref-type="table"}). Mean tumor size was 14.8(range 3.5--40.0) cm. Overall survival of tumor ≤10 cm and\>10 cm were of no difference (Table [5](#Tab5){ref-type="table"}). Median (Q25, Q75) preoperative SCC-Ag was 7.4 (3.0, 20.0) ng/mL, CA125 was 64.4 (34.2, 143.0) U/mL, CA19--9 was 144.0 (45.1, 943.5) U/mL and CEA was 6.9 (2.5, 23.0) ng/mL. Abdominal pain and palpable abdominal mass were two major clinical manifestations of SCC transformation in MCTO, occurring in 47.3 and 26% of all cases, respectively. StageI,II, III and IV accounted for 50.0, 18.8, 26.8 and 4.4% of all cases, respectively (Table [4](#Tab4){ref-type="table"}). Compared with stage I, stage II, III and IV were associated with worse prognosis (*P* \< 0.01) (Table [5](#Tab5){ref-type="table"}, Fig. [2a](#Fig2){ref-type="fig"}). 5-year overall survival was 85.8, 39.1, 26.2 and 0% for stage I, II, III, and IV, respectively. There was no interaction between histology grade and survival (Table [5](#Tab5){ref-type="table"}).Table 4Clinical features of SCC transformation in MCTOResultsAge, years (*n* = 434)^a^53.5 (13.9, 19--87)\<45 years121≥45 years313Tumor size, cm (*n* = 316)^a^14.8 (5.9, 3.5--40)Preoperative tumor markers^b^SCC-Ag, ng/mL (*n* = 78)7.4 (3.0, 20.0)CA125, U/mL(*n* = 104)64.4 (34.2, 143.0)CA19--9,U/mL (*n* = 65)144.0 (45.1, 943.5)CEA, ng/mL (*n* = 51)6.9 (2.5, 23.0)Clinical manifestation (*n* = 204)Abdominal/pelvic pain139Mass53Abdominal bloating49Physical examination10Urinary frequency6Weight loss11Change in bowel habits20Fever7FIGO staging (*n* = 414)I207II78III111IV18Histological grade (*n* = 203)154284365^a^Mean (SD, range); ^b^ Median (Q25, Q75)Table 5Clinical features and overall survival of SCC transformation in MCTOVariableUnivariate HR (95% CI)*P* valueAge (*n* = 370) \<45 (*n* = 105)Reference ≥45 (*n* = 265)1.91 (1.26--2.89)\<0.01^\*^Diameter (cm) (*n* = 265) (*n* = 265) ≤10 (*n* = 67)Reference \>10 (*n* = 198)1.08 (0.70--1.68)0.73Stage (*n* = 348) I (*n* = 172)Reference II (*n* = 70)6.92 (3.98--12.06)\<0.01^\*^ III (*n* = 92)9.32 (5.58--15.59)\<0.01^\*^ IV (*n* = 14)16.45(7.95--34.02)\<0.01^\*^Grade (*n* = 169) 1 (n = 43)Reference 2 (*n* = 69)1.60 (0.81--3.15)0.17 3 (*n* = 57)1.76 (0.89--3.49)0.10Cox proportional hazard regression model analysisFig. 2**a**. FIGO stage and overall survival. **b**. hysterectomy and overall survival. **c**. chemotherapy and overall survival for stage II, III, IV. **d**. chemotherapy with platinum and overall survival for stage II, III, IV

As for treatment, hysterectomy can reduce death risk (*P* \< 0.01) (Table [6](#Tab6){ref-type="table"}, Fig. [2b](#Fig2){ref-type="fig"}) whereas lymphadenectomy did not improve survival. Omentectomy did not improve survival with univariant analysis, while after adjusted with International Federation of Gynecology and Obstetrics (FIGO) stage, omentectomy was associated with better prognosis (*P* = 0.04) (Table [6](#Tab6){ref-type="table"}). 24 of the 51 patients younger than 45 years old with stageIA orIC underwent fertility-sparing surgery. There was no difference in mortality between fertility-sparing and radical surgery (*P* = 1.00).Table 6Surgery modality and overall survival of SCC transformation in MCTOSurgeryUnivariate HR (95% CI)*P* valueStage-adjusted HR (95% CI)*P* valueHysterectomy (325) Yes (232) vs No (93)0.60 (0.42--0.85)\< 0.01^\*^0.51 (0.36--0.74)\< 0.01^\*^\\Lymphadenectomy (325) Yes (69) vs No (256)0.69 (0.43--1.09)0.110.76 (0.47--1.22)0.25Omentectomy (313) Yes (120) vs No (193)1.04 (0.72--1.48)0.850.66 (0.45--0.98)0.04Cox proportional hazard regression model analysis

Efficacy of postoperative adjuvant therapy was analyzed in a subgroup of SCC transformation in MCTO with stage II, III and IV. Adjuvant chemotherapy can improve survival in patients with advanced stage (*P* = 0.02) (Table [7](#Tab7){ref-type="table"}, Fig. [2c](#Fig2){ref-type="fig"}), and chemotherapy with platinum was related to better prognosis compared with other drugs (*P* = 0.02) (Table [8](#Tab8){ref-type="table"}, Fig. [2d](#Fig2){ref-type="fig"}). However, radiotherapy and chemoradiotherapy did not improve survival (Table [7](#Tab7){ref-type="table"}).Table 7Treatments and overall survival of SCC transformation in MCTO of stage II, III and IVTreatmentUnivariate HR (95% CI)*P* valueStage-adjusted HR (95% CI)*P* valueChemotherapy (170) Yes (118) vs No (52)0.60 (0.40--0.91)0.02^\*^0.56 (0.37--0.86)0.01^\*^Radiotherapy (170) Yes (50) vs No (120)0.80 (0.52--1.21)0.290.89 (0.57--1.38)0.60Chemoradiotherapy (170) Yes (31) vs No (139)0.71(0.43--1.16)0.170.73 (0.44--1.21)0.22Cox proportional hazard regression model analysisTable 8Chemotherapy regimen and overall survival of SCC transformation in MCTO of stage II, III and IVDrug (*n* = 103)Univariate HR (95% CI)*P* valueStage-adjusted HR (95% CI)*P* valuePlatinum derivatives (n = 92)0.43 (0.21--0.87)0.02^\*^0.41 (0.20--0.84)0.02^\*^Taxanes (*n* = 29)1.09 (0.61--1.98)0.781.10 (0.60--2.00)0.76Vinca alkaloids (*n* = 21)0.59 (0.30--1.20)0.140.48 (0.23--1.01)0.05Alkylating agents (*n* = 15)1.05 (0.53--2.09)0.880.84 (0.38--1.84)0.665-FU (n = 16)0.77 (0.36--1.62)0.500.82 (0.39--1.75)0.61Bleomycin (*n* = 36)0.94 (0.55--1.61)0.820.85 (0.48--1.50)0.57VP-16 (*n* = 12)0.76 (0.33--1.78)0.530.82 (0.35--1.92)0.64Cox proportional hazard regression model analysis

Discussion {#Sec6}
==========

SCC transformation in MCTO is the most common malignant transformation of MCTO \[[@CR4]\] and is also the most common cause of SCC of the ovary \[[@CR9], [@CR104]\]. SCC transformation in MCTO may be a continuous process of squamous metaplasia, atypical hyperplasia, carcinoma in situ, interstitial infiltration and invasive carcinoma \[[@CR14], [@CR105]\]. The mean age of MCTO patients without malignant transformation is 32.7 years \[[@CR1]\] while the mean age of SCC transformation in MCTO in our study is 53.5 years. Some cases have a history of MCTO \[[@CR19], [@CR70]\], suggesting that unmanaged MCTO may undergo malignant transformation. SCC transformation in MCTO may be associated with high-risk human papilloma virus (HPV) infection \[[@CR15]\], and alterations in p53 and p16 may be involved in the process of malignant transformation \[[@CR16], [@CR17], [@CR106]\]. A recent next-generation sequencing analysis indicated that TP53 mutation was detected in 80% of SCC transformation in MCTO cases and mutation in TP53 correlated with better prognosis. PIK3CA and CDKN2A were altered in 52 and 44% cases, respectively \[[@CR107]\].

In this study, 50% of cases are diagnosed in FIGO stage I. The proportion of stage I is much higher than that of all ovarian cancer, which is 15% \[[@CR108]\]. More SCC transformation in MCTO cases can be detected in early stage because the malignant component originates from epithelium of preexistent MCTO \[[@CR14]\], which is a gradual process, and is often found unexpectedly after resection of adnexal mass \[[@CR1]\]. The same as epithelial ovarian cancer, FIGO stage is an independent prognostic factor for SCC transformation in MCTO. In this study, the 5-year survival rate of stage I patients is 85%, while in patients with stage II, III, the 5-year survival rate is less than 50%. So early detection is of great value and can improve the prognosis of SCC transformation in MCTO.

Comprehensive staging surgery is the standard treatment for ovarian cancer. Hysterectomy and omentectomy appear to improve survival of SCC transformation in MCTO, while lymph node dissection does not affect overall survival in our analysis. This observation suggests that local dissemination is an important metastasis manner of SCC transformation in MCTO. The cases included in this study are retrospective and are from multiple medical centers. What's more, some cases do not point out the exact scope of lymph node dissection. Since lymph node dissection is part of comprehensive staging surgery, we are in favor of performing lymphadenectomy despite the negative result in this study.

For patients with epithelial ovarian cancer in stages IA/IC, unilateral salpingo-oophorectomy is an optional treatment. For patients with malignant ovarian germ cell tumors, regardless of stage, fertility-sparing surgery can be done and after delivery a comprehensive operation should be conducted \[[@CR13]\]. Our study suggests that for SCC transformation in MCTO, it is safe and feasible to perform fertility-sparing surgery in patients younger than 45 years of age old with stage IA/IC. There are cases of successful pregnancies after fertility-sparing surgery \[[@CR57], [@CR74], [@CR83]\].

The recommend initial chemotherapy regimen for ovarian germ cell tumor and for epithelial ovarian cancer is bleomycin/etoposide/cisplatin (BEP) and paclitaxel/carboplatin (TC), respectively. Currently there is no recognized first-line adjuvant therapy for SCC transformation in MCTO, though chemotherapy can improve prognosis of patients with SCC transformation in MCTO of advanced stage. Hackethal et al. suggest that chemotherapy with alkylating agents is related to better prognosis in patients with SCC transformation in MCTO \[[@CR109]\]. However, in our study with the analysis of patients of stage II, III and IV, alkylating agents did not promote overall survival compared with others. We recommend individualized and integrated treatment based on platinum-based chemotherapy.

The histology of SCC transformation in MCTO is squamous cell carcinoma and genetic study indicates that SCC transformation in MCTO has features in common with other SCC \[[@CR107]\], which are often sensitive to radiotherapy. However, our results suggested that radiotherapy does not improve prognosis of SCC transformation in MCTO. Whenever applied, doctors should pay attention to complications of radiotherapy \[[@CR110]\].

This study has some limitations. Firstly, since the analysis is mostly based on review on published data, we cannot avoid the publication bias. Secondly, although preoperative detection of SCC transformation in MCTO is of great value, in our study we do not conduct the analysis because only a few papers reported the imaging features and serum markers \[[@CR111], [@CR112]\]. The size of invasive component, which is possibly related to prognosis, is not available due to the retrospective study design. Moreover, few publications report cycles of chemotherapy, thus we do not investigate the optimal course of treatment. We recommend presentation of such information whenever reporting cases. Lastly, our results should be treated with caution, as the included studies span a prolonged time period (\~ 40 years) during which changes in medical and therapeutic strategies may have changed.

Conclusions {#Sec7}
===========

SCC transformation in MCTO is a rare malignancy mainly occurs in older age. Early detection is important for better prognosis. Hysterectomy and platinum-based chemotherapy are associated with better survival. Fertility-sparing surgery is feasible for young patients with early stage. Due to the retrospective study design and limited data available, the results should be interpreted with caution. More reports are in need to elucidate the biology of SCC transformation in MCTO.
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Additional file 1:**Figure S1.** The flow chart of study selection and case inclusion. **Table S1.** Stage of different treatment group in survival analysis. (DOCX 40 kb)

BEP

:   Bleomycin/etoposide/cisplatin

BPALND

:   Bilateral para-aortic lymph node dissection

BPLND

:   Bilateral pelvic lymph node dissection

BSO

:   Bilateral salpingo-oophorectomy

DOD

:   Die of disease

FIGO

:   International Federation of Gynecology and Obstetrics

HPV

:   Human papilloma virus

HR

:   Hazard ratio

LSO

:   Left salpingo-oophorectomy

MCTO

:   Mature cystic teratoma of the ovary

NED

:   No evidence of disease

SCC

:   Squamous cell carcinoma

TC

:   Paclitaxel/carboplatin

TH

:   Total hysterectomy
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